Importantly, the analysis for tumor-infiltrating T lymphocytes in P4 tumors demonstrated enhanced expression of the immune checkpoint inhibitor CTLA4, while those in P1 demonstrated a higher frequency of the effector Th17/Th1 phenotype. Here, CTLA4 is linked to neoplasm.